CMS Honored with the 2026 Stock Star Capital Power “Outstanding Listed Company Award”

On November 6, 2026, at the 14th “Capital Power” annual brand event hosted by Stock Star, CMS was honored with the “Outstanding Listed Company Award” in recognition of its outstanding performance in differentiated innovation strategy, solid operating results, and corporate governance.

Since its launch in 2012, Stock Star’s “Capital Power” annual brand event has been held for 14 consecutive editions, dedicated to identifying outstanding companies in the capital market and providing evaluation and benchmarks for the development of the financial industry and listed companies. The “Outstanding Listed Company Award” focuses on assessing a company’s products and technologies competitiveness, value creation capability, operating resilience, investment in innovative R&D, and corporate governance standards. This award underscores the capital market’s full recognition of CMS’s overall strength, innovation achievements, and sound governance.

CMS has been deeply engaged in the pharmaceutical industry for more than 30 years, focusing on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. To date, the Company has 9 commercialized innovative drugs and more than 40 exclusive drugs and other products on the market. Meanwhile, the Company has continued to increase R&D investment to build long-term growth momentum. In 2025, total R&D expenditure (including both capitalized and expensed R&D expenditure) reached RMB 1.058 billion, up 40.5% year on year and accounting for 12.9% of revenue; in the first half of 2026, this proportion further increased to 18.3%. To date, the Company has more than 40 innovative pipelines under development: 4 innovative drugs (covering 5 indications) are under NDA review; approximately 15 are in clinical development (including 6 in-house R&D products); and more than 20 in-house R&D pipelines are in the preclinical stage. In addition, the Company has continued to improve its governance system and risk management mechanisms, enhancing its standardized operations. In 2026, it received an “AAA” rating from MSCI ESG, an “A” rating in the Hang Seng Sustainability Index, and was selected for the S&P Global Sustainability Yearbook (Global Edition) for the second consecutive year.

At this new stage of development, CMS will continue to deepen its presence in its advantageous specialty fields, uphold equal emphasis on innovation-driven development and value creation, continuously enhance its full lifecycle product management capabilities, and continue to drive  the commercialization of innovation achievements and high-quality growth in operating performance.

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.